Stimulating effects of H1-antagonists

Current Pharmaceutical Design

Volumn 12, Issue 20, 2006, Pages 2501-2509

  Theunissen, Eef L ^a   Vermeeren, Annemiek ^a   Vuurman, Eric F P M ^a   Ramaekers, Johannes G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antihistamine; Attention; Desloratadine; Dopamine; Ebastine; Fexofenadine; GABA; H3 receptor; Performance; Stimulant; Terfenadine

Indexed keywords

4 AMINOBUTYRIC ACID; ACRIVASTINE; ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CAFFEINE; CETIRIZINE; CHLORCYCLIZINE; CHLORPHENIRAMINE; CIPROXIFAN; CLEMASTINE; CLEMIZOLE; DESLORATADINE; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVODOPA; LORATADINE; MEPYRAMINE; PARGYLINE; PROMETHAZINE; TERFENADINE; TRIPELENNAMINE; TRIPROLIDINE; UNINDEXED DRUG;

ALERTNESS; ATTENTION; BINDING AFFINITY; CLINICAL TRIAL; COGNITION; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRIVING ABILITY; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; EVIDENCE BASED MEDICINE; EYE HAND COORDINATION; GABAERGIC SYSTEM; HISTAMINE RELEASE; HUMAN; LATENT PERIOD; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTRANSMISSION; NIGHT SLEEP; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; REACTION TIME; REM SLEEP; RETREATMENT; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP TIME; SOMNOLENCE; SYSTEMATIC REVIEW; TASK PERFORMANCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VISUOMOTOR COORDINATION;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE UPTAKE INHIBITORS; GAMMA-AMINOBUTYRIC ACID; HISTAMINE ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; HUMANS; RECEPTORS, HISTAMINE H3;

EID: 33745736006     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698800     Document Type: Review

References (69)

1. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-72.
2. Steinbusch HW. Distribution of histaminergic neurons and fibers in rat brain. Comparison with noradrenergic and serotonergic innervation of the vestibular system. Acta Otolaryngol Suppl (Stockh) 1991; 479: 12-23.
3. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic, neurons. Sleep Med Rev 2000; 4: 471-503.
4. Onoe H, Yamatodani A, Watanabe T, Ono K, Mochizuki T, Wada H, et al. Prostaglandin E2 and histamine in the posterior hypothalamus. J Sleep Res 1992; 1: 166.
5. Yamatodani A, Inagaki N, Panula P, Itowi N, Watanabe T, Wada H. In: Born GVR Ed. Handbook of Experimental Pharmacology. Berlin, Springer-Verlag 1991; 243-283.
6. Vanni Mercier G, Gigout S, Debilly G, Lin JS. Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav Brain Res 2003; 144: 227-41.
7. Ramaekers JG, Uiterwijk MM, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363-9.
8. Vuurman EF, Uiterwijk MM, Rosenzweig P, O'Hanlon F. Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 253-259.
9. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. Br Med J 2000; 320: 1184-6.
10. Tashiro M, Mochizuki H, Iwabuchi K, Sakurada Y, Itoh M, Watanabe T, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002; 72: 409-14.
11. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, et al. Central Effects of Fexofenadine and Cetirizine: Measurement of Psychomotor Performance, Subjective Sleepiness, and Brain Histamine H1-Receptor Occupancy Using 11C-Doxepin Positron Emission Tomography. J Clin Pharmacol 2004; 44: 890-900.
12. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allegry 1999; 29: 29-36.
13. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, et al. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 2001; 52: 501-9.
14. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol 1978; 6: 31-35.
15. Vermeeren A, O'Hanlon JF. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998; 101: 306-311.
16. Moskowitz H, Burns MB. Effects of terfenadine, diphenhydramine, and placebo on skills performance. Cutis 1988, 42: 14-18.
17. Mattila MJ, Kuitunen T, Pletan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 1992, 43: 179-184.
18. Vuurman EFPM, Rikken GH, Muntjewerff ND, de Halleux F, Ramaekers JG. Effects of desloratadine, diphenhydramme, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004; 60: 307-313.
19. Theunissen EL, Jonkman LM, Kuypers KPC, Ramaekers JG. Stimulating effects of fexofenadine under high workload conditions. A combined neurophysiological and behavioral approach. J Psychopharmacol (Oxf). In press.
20. Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy 1999; 22: 1-11.
21. Betts T, Kenwood C, Dalby G, Hull B, Wild J. A comparison of the effects of two non-sedating antihistamines (terfenadine and cetirizine) on tests of CNS function including driving. J Psychopharmacol (Oxf) 1989; 3/4: 101P (Abstract).
22. Betts T, Markman D, Debenham S, Mortiboy D, McKevitt T. Effects of two antihistamine drugs on actual driving performance. Br Med J (Chu Res Ed) 1984; 288: 281-2.
23. Riedel WJ, Schoenmakers EAJM, O'Hanlon JF. In: Kalinger MA Ed. Management of allergy in the 1990s. Toronto, Hans Huber. 1989; 38-49.
24. Volkerts ER, Van Willigenburg AP, Van Laar MW, Maes PA. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharmacol Clin Exp 1992; 7: 227-238.
25. Ramaekers JG, O'Hanlon JF. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47: 261-266.
26. O'Hanlon JF, Haak TW, Blaauw GJ, Riemersma JB. Diazepam impairs lateral position control in highway driving. Science 1982; 217: 79-81.
27. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004; 18: 297-328.
28. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003; 64: 20-9.
29. Simons FE, Reggin JD, Roberts JR, Simons KJ. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994; 124: 979-83.
30. Simons FE, Fraser TG, Reggin JD, Simons KJ. Comparison of the central nervous systems effects produced by six H1- receptor antagonists. Clin Exp Allergy 1996; 26: 1092-7.
31. Reinberg A, Levi F, Guillet P, Burke JT, Nicolai A. Chronopharmacological study of antihistamines in man with special references to terfenadine. Eur J Clin Pharmacol 1978; 14: 245-252
32. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol 1978; 6: 31-35.
33. De Vries G, de Waard D, Brookhuis KA. A double blind study to compare the acute and subcbronic effects of ebastine 10, 20, 30 mg o.d., triprolidine 10 mg o.d. and placebo on car driving performance. Traffic Research Center University of Groningen 1989; VK 89-22
34. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50: 234-342.
35. Ridout F, Shamsi Z, Meadows R, Johnson S, Hindmarch I. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003; 25: 1518-1538.
36. Dringenberg HC, de Souza-Silva MA, Schwarting RK, Huston JP. Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 423-429.
37. Robbins TW. Arousal systems and attentional processes. Biol Psychol 1997; 45: 57-71.
38. Fleming K, Bigelow LB, Weinberger DR, Goldberg TE. Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 1995; 31: 357-62.
39. Johnson B, Overton D, Wells L, Kenny P, Abramson D, Dhother S, et al. Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts. Psychiatry Res 1998; 77: 35-42.
40. Vermeeren A. Hypnotics and antihistamines. Effects on cognitive functions and driving performance. Brain and Behavior Institute, Maastricht University 2003.
41. Oishi R, Shishido S, Yamori M, Saeki K. Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 140-144.
42. Matsunaga K, Sato T, Shuto H, Tsuruta Y, Suemaru K, Gomita Y, et al. Inhibition of neuronal dopamine uptake by some antiallergic drugs. Eur J Pharmacol 1998; 350: 165-169
43. Bergman J, Spealman RD. Behavioral effects of histamine H1 antagonists: comparison with other drugs and modification by haloperidol. J Pharmacol Exp Ther 1988; 245: 471-478.
44. Suzuki T, Mori T, Tsuji M, Nomura M, Misawa M, Onodera K. Evaluation of the histamine H1-antagonist-induced place preference in rats. Jpn J Pharmacol 1999; 81: 332-338.
45. Sato T, Suemaru K, Matsunaga K, Hamaoka S, Gomita Y, Oishi R. Potentiation of L-dopa-induced behavioral excitement by histamine H1-receptor antagonists in mice. Jpn J Pharmacol 1996; 71: 81-4.
46. Leshner AI, Koob GF. Drugs of abuse and the brain. Proc Assoc Am Physicians 1999; 111: 99-108.
47. Korotkova TM, Haas HL, Brown RE. Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro. Neurosci Lett 2002; 320: 133-6.
48. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-7.
49. Blandina P, Bacciottini L, Giovannini MG, Mannaioni PF. In: Leurs R, Timmerman H Eds, The Histamine H3 Receptor. Amsterdam, Elsevier 1998; 27-40.
50. Sharif NA, Su SX, Yanni JM. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10: 653-64.
51. Monti JM, Jantos H, Boussard M, Altier H, Orellana C, Olivera S. Effects of selective activation or blockade of the histamine H3 receptor on sleep and wakefulness. Eur J Pharmacol 1991; 205: 283-7.
52. Monti JM, Jantos H, Ponzoni A, Monti D. Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996; 15: 31-5.
53. Schlicker E, Kathmann M. In: Leurs R, Timmerman H Eds, The histamine H3 receptor. A target for new drugs. Amsterdam, Elsevier. 1998; 13-26.
54. Witkin JM, Nelson DL. Selective histamine H(3) receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004; 103: 1-20.
55. Ligneau X, Lin J, Vanni Mercier G, Jouvet M, Muir JL, Ganellin CR, et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 1998; 287: 658-66.
56. Parmentier R, Ohtsu H, Djebbara Hannas Z, Valatx JL, Watanabe T, Lin JS. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. Journal of neuroscience the official journal of the Society for Neuroscience 2002; 22: 7695-711.
57. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med 2001; 43: 64-71.
58. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21: 7-13.
59. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71: 121-6.
60. Vohora D. Histamine-selective H3 receptor ligands and cognitive functions: an overview. IDrugs 2004; 7: 667-73.
61. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol 2004; 68: 933-45.
62. Prast H, Argyriou A, Philippu A. Histaminergic neurons facilitate social memory in rats. Brain Res 1996; 734: 316-8.
63. Bernaerts P, Lamberty Y, Tirelli E. Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behav Brain Res 2004; 154: 211-9.
64. Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R, et al. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 2002; 131: 151-61.
65. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, et al. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 2003; 305: 897-908.
66. Valk PJ, Van Roon DB, Simons RM, Rikken G. Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat Space Environ Med 2004; 75: 433-8.
67. de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005; 11(27): 3561-94.
68. Tsang SY, Xue H. Development of effective therapeutics targeting the GABAA receptor: naturally occurring alternatives. Curr Pharm Des 2004; 10(9): 1035-44.
69. Walsh GM. Novel therapies for asthma - advances and problems. Curr Pharm Des 2005, 11(23): 3027-38.